GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laboratorio Reig Jofre SA (XMAD:RJF) » Definitions » EV-to-EBIT

Laboratorio Reig Jofre (XMAD:RJF) EV-to-EBIT : 61.32 (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Laboratorio Reig Jofre EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Laboratorio Reig Jofre's Enterprise Value is €250.4 Mil. Laboratorio Reig Jofre's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €4.1 Mil. Therefore, Laboratorio Reig Jofre's EV-to-EBIT for today is 61.32.

The historical rank and industry rank for Laboratorio Reig Jofre's EV-to-EBIT or its related term are showing as below:

XMAD:RJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 2.47   Med: 31.82   Max: 152.48
Current: 61.32

During the past 13 years, the highest EV-to-EBIT of Laboratorio Reig Jofre was 152.48. The lowest was 2.47. And the median was 31.82.

XMAD:RJF's EV-to-EBIT is ranked worse than
90.27% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.21 vs XMAD:RJF: 61.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Laboratorio Reig Jofre's Enterprise Value for the quarter that ended in Dec. 2023 was €224.3 Mil. Laboratorio Reig Jofre's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €4.1 Mil. Laboratorio Reig Jofre's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.82%.


Laboratorio Reig Jofre EV-to-EBIT Historical Data

The historical data trend for Laboratorio Reig Jofre's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Reig Jofre EV-to-EBIT Chart

Laboratorio Reig Jofre Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.65 53.48 48.36 23.74 19.96

Laboratorio Reig Jofre Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 190.24 23.74 53.51 46.37 19.96

Competitive Comparison of Laboratorio Reig Jofre's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorio Reig Jofre's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's EV-to-EBIT falls into.



Laboratorio Reig Jofre EV-to-EBIT Calculation

Laboratorio Reig Jofre's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=250.440/4.084
=61.32

Laboratorio Reig Jofre's current Enterprise Value is €250.4 Mil.
Laboratorio Reig Jofre's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorio Reig Jofre  (XMAD:RJF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Laboratorio Reig Jofre's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=4.084/224.33375
=1.82 %

Laboratorio Reig Jofre's Enterprise Value for the quarter that ended in Dec. 2023 was €224.3 Mil.
Laboratorio Reig Jofre's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorio Reig Jofre EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Laboratorio Reig Jofre's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorio Reig Jofre (XMAD:RJF) Business Description

Traded in Other Exchanges
Address
Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.